Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/Ib study whose purpose is to find out if combining an experimental drug
called binimetinib with pembrolizumab is beneficial in people who have advanced non-small
cell lung cancer. This study may also see if the combination is safe and may also find the
best dose of binimetinib that should be added to pembrolizumab.